Post lockdown COVID-19 seroprevalence and circulation at the time of delivery, France

  1. Jérémie Mattern
  2. Christelle Vauloup-Fellous
  3. Hoda Zakaria
  4. Alexandra Benachi
  5. Julie Carrara
  6. Alexandra Letourneau
  7. Nadège Bourgeois-Nicolaos
  8. Daniele De Luca
  9. Florence Doucet-Populaire
  10. Alexandre J. Vivanti

Reviewed by

Read the full article See related articles

Listed in

Log in to save this article

Abstract

No abstract available

Article activity feed

  1. Version published to 10.1371/journal.pone.0240782
  2. ScreenIT

    SciScore for 10.1101/2020.07.14.20153304: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    Institutional Review Board StatementIRB: This study was approved by the institutional review board of the French College of Obstetricians and Gynecologists (2020-OBST-0408) and was performed in accordance with the Declaration of Helsinki.
    Consent: All patients gave written consent.
    Randomizationnot detected.
    Blindingnot detected.
    Power Analysisnot detected.
    Sex as a biological variableA questionnaire was distributed to all included women, who were asked about symptoms (fever, cough, dyspnea, myalgia, anosmia, diarrhea and rash) affecting them and/or close relatives (household residents) from January 1 to their delivery, and if there were symptoms they were asked for the date of onset.

    Table 2: Resources

    Software and Algorithms
    SentencesResources
    Serology testing: Serum samples were run on the Abbott Architect instrument using the Abbott SARS- CoV-2 IgG assay (Abbott, Sligo, Ireland) following the manufacturer’s instructions.
    Abbott
    suggested: (Abbott, RRID:SCR_010477)
    The GeneFinder assay is a molecular in vitro test utilizing one-step reverse transcription real- time PCR to detect the RNA-dependent RNA polymerase, the envelope gene (E) and the nucleocapsid gene (N), as described in international guidelines (Corman et al.[8]) The Xpert Xpress SARS-CoV-2 assay (Cepheid) and the GenMark ePlex SARS-CoV- 2 assay are sample-to-answer molecular diagnostic platforms.
    GeneFinder
    suggested: (GENEFINDER, RRID:SCR_009190)

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

    Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

    Results from TrialIdentifier: No clinical trial numbers were referenced.

    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

    Results from JetFighter: We did not find any issues relating to colormaps.

    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

  3. Version published to 10.1101/2020.07.14.20153304v1 on medRxiv